Akari Therapeutics, Plc (AKTX) Financials

AKTX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 38.6 million 20.0 million
March 31, 2026 33.9 million 19.5 million
Dec. 31, 2025 47.9 million 19.6 million
Sept. 30, 2025 45.4 million 22.7 million

AKTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -3.1 million 711000
March 31, 2026 -2.5 million 305000
Dec. 31, 2025 -3.0 million 1.2 million
Sept. 30, 2025 -2.1 million 685000

AKTX Net Income

No data available :(

AKTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 7.7 million - -
March 31, 2026 2.8 million - -
Dec. 31, 2025 5.2 million - -
Sept. 30, 2025 2.5 million - -

AKTX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 1.8 million
March 31, 2026 21040
Dec. 31, 2025 21040
Sept. 30, 2025 16331

AKTX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 2.1 million 2.5 million -
March 31, 2026 - 1.5 million 2.2 million -
Dec. 31, 2025 - 1.1 million 2.1 million -
Sept. 30, 2025 3 249000 2.0 million -

AKTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - -
Dec. 31, 2025 - -
Sept. 30, 2025 - -

AKTX

Price: $8.37

52 week price:
3.02
44.00

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United Kingdom

Volume: 16739

Ebitda: -8.5 million

Market Capitalization: 19.8 million

Links: